News & Analysis as of

Pharmaceutical Industry › Public Offerings

Latham & Watkins LLP

Life Sciences Product Development Needs More Creative Fundraising

Latham & Watkins LLP on

The life sciences industry depended historically on public offerings for fundraising to support costs of developing therapeutic pharmaceutical and biologic products. The average cost of discovering and developing these...more

Mintz - Intellectual Property Viewpoints

Picture Claims as an Effective Patent Strategy: Top 10 Reasons to Precisely Tailor Your Patent Claim

Mintz - Intellectual Property Viewpoints on

A “picture” claim refers to a patent claim precisely tailored to track a particular product’s important advantages and features. When drafting a patent application, one should describe various embodiments of the invention and...more

Robins Kaplan LLP

Financial Daily Dose 9.9.2019 | Top Story: Fed on Track to Cut Rates Again in September

Robins Kaplan LLP on

Friday remarks from Fed Chair Powell in Zurich confirmed the central bank’s dedication to keeping the US economic expansion on track and appear to have signaled the Fed’s plan to cut interest rates for a second time this...more

Mintz - Securities Litigation Viewpoints

Court Overseeing the Valeant Securities Litigation Issues a Highly Anticipated Decision Ruling that Alleged Misstatements in Rule...

Mintz - Securities Litigation Viewpoints on

In an April 28, 2017 ruling on a motion to dismiss in the In re Valeant Pharmaceuticals International, Inc. Securities Litigation (the “Valeant Litigation”), the U.S. District Court for the District of New Jersey addressed an...more

Goodwin

Deal Watch – Coherus Announces Public Common Stock Offering

Goodwin on

Coherus BioSciences, Inc. announced yesterday that it had commenced an underwritten public offering of common stock valued at $125 million. These shares are being offered directly by Coherus in conjunction with an expected...more

King & Spalding

Eleventh Circuit Confirms that Issuers are not Required to Disclose Retention of Outside Promotional Firms

King & Spalding on

On December 15, 2016, the United States Court of Appeals for the Eleventh Circuit affirmed the dismissal of a securities class action against Galectin Therapeutics Inc., a Georgia-based biotechnology company. The suit...more

Carlton Fields

Dismissal for Drugmaker Affirmed: Galectin Had No Duty to Disclose Payments to Promoters

Carlton Fields on

In re: Galectin Therapeutics, Inc. Securities Litigation, No. 16-10324, 2016 WL 7240146, ____ , F2d ___ (11th Cir. Dec. 15, 2016). The Eleventh Circuit recently addressed the circumstances under which a public company...more

WilmerHale

February 2015 IPO Market Review

WilmerHale on

Momentum in the IPO market ebbed in February with the month producing only six IPOs—the lowest monthly figure since the four IPOs in February 2013. The 19 IPOs over the first two months of 2015 are just over half the total of...more

WilmerHale

January 2015 IPO Market Review

WilmerHale on

The January IPO market produced 13 IPOs with gross proceeds of $1.24 billion, the first IPO not coming until mid-month. The last two days of January alone produced seven IPOs....more

9 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide